← 返回专利悬崖列表
CAS 501-53-1
benzyl carbonochloridate(Phenylmethyl)carbonochloridate
登记编号：RIVA-022、(VII)101438-22-a、Vornorexant-004
应用背景（按来源药适应症）
肺栓塞利伐沙班中风利伐沙班先天性心脏缺损利伐沙班血栓形成利伐沙班静脉血栓栓塞利伐沙班冠状动脉疾病利伐沙班乳腺癌Paclitaxel/Encequidar mesylate腺癌Paclitaxel/Encequidar mesylate血管肉瘤Paclitaxel/Encequidar mesylate实体瘤Paclitaxel/Encequidar mesylate胰腺癌紫杉醇非小细胞肺癌紫杉醇霍奇金病紫杉醇精原细胞瘤紫杉醇卵巢癌紫杉醇乳腺癌紫杉醇入睡和睡眠障碍Vornorexant肝功能衰退Vornorexant睡眠呼吸暂停Vornorexant
来源药（使用该中间体的合成路线）
| 品种 | 梯队 | 到期年 |
|---|---|---|
| 利伐沙班Rivaroxaban | Tier A · 立即攻坚 | 2026 |
| Paclitaxel/Encequidar mesylate | Tier C · 观察 / 贸易 | - |
| 紫杉醇Paclitaxel | Tier B · 提前布局 | - |
| Vornorexant | Tier C · 观察 / 贸易 | - |
合成路线中的位置（上下游链）
按路线登记顺序排列，左→右为合成方向；高亮为当前 CAS，其余可点击跳转对应档案。
2-chloroacetyl chloride→4-(4-nitrophenyl)morpholin-3-one→4-(4-aminophenyl)morpholin-3-one→5-chlorothiophene-2-carbonyl chloride→2-(phenylamino)ethan-1-ol→4-phenylmorpholin-3-one→benzyl carbonochloridate→benzyl (4-(3-oxomorpholino)phenyl)carbamate→(R)-oxiran-2-ylmethyl butyrate→(R)-4-(4-(5-(hydroxymethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one→(R)-(2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl methanesulfonate→2-methylpropan-2-amine→(S)-4-(4-(5-((tert-butylamino)methyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one→(S)-N-(tert-butyl)-5-chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)thiophene-2-carboxamide
(2R,3S)-3-phenyloxirane-2-carboxylic acid→(2-Hydroxyethyl)trimethylsilane→2-(trimethylsilyl)ethyl (2R,3S)-3-phenyloxirane-2-carboxylate→2-(trimethylsilyl)ethyl (2S,3S)-3-bromo-2-hydroxy-3-phenylpropanoate→alpha-Chlorobenzaldehyde→2-(trimethylsilyl)ethyl (2R,3S)-3-azido-2-hydroxy-3-phenylpropanoate→2-(trimethylsilyl)ethyl (2R,3S)-3-amino-2-hydroxy-3-phenylpropanoate→(Phenylmethyl)carbonochloridate→2-(trimethylsilyl)ethyl (2R,3S)-3-{[(benzyloxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate→2-(trimethylsilyl)ethyl (2R,3S)-2-(benzoyloxy)-3-{[(benzyloxy)carbonyl]amino}-3-phenylpropanoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-Bis(acetyloxy)-1,15-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-15-{[(2R,3S)-2-(benzoyloxy)-3-{[(benzyloxy)carbonyl]amino}-3-phenylpropanoyl]oxy}-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate
(2R,3S)-3-phenyloxirane-2-carboxylic acid→(2-Hydroxyethyl)trimethylsilane→2-(trimethylsilyl)ethyl (2R,3S)-3-phenyloxirane-2-carboxylate→2-(trimethylsilyl)ethyl (2S,3S)-3-bromo-2-hydroxy-3-phenylpropanoate→alpha-Chlorobenzaldehyde→2-(trimethylsilyl)ethyl (2R,3S)-3-azido-2-hydroxy-3-phenylpropanoate→2-(trimethylsilyl)ethyl (2R,3S)-3-amino-2-hydroxy-3-phenylpropanoate→(Phenylmethyl)carbonochloridate→2-(trimethylsilyl)ethyl (2R,3S)-3-{[(benzyloxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoate→2-(trimethylsilyl)ethyl (2R,3S)-2-(benzoyloxy)-3-{[(benzyloxy)carbonyl]amino}-3-phenylpropanoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-Bis(acetyloxy)-1,15-dihydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate→(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-15-{[(2R,3S)-2-(benzoyloxy)-3-{[(benzyloxy)carbonyl]amino}-3-phenylpropanoyl]oxy}-1-hydroxy-10,14,17,17-tetramethyl-11-oxo-9-[(triethylsilyl)oxy]-6-oxatetracyclo[11.3.1.0(3,10).0(4,7)]heptadec-13-en-2-yl benzoate
3-aminopropan-1-ol→2-oxoacetic acid→1,3-oxazinane-2-carboxylic acid→benzyl carbonochloridate→3-((benzyloxy)carbonyl)-1,3-oxazinane-2-carboxylic acid→(R)-2-amino-2-phenylethan-1-ol→(S)-3-((benzyloxy)carbonyl)-1,3-oxazinane-2-carboxylic acid, (R)-2-amino-2-phenylethan-1-ol→(S)-3-((benzyloxy)carbonyl)-1,3-oxazinane-2-carboxylic acid→3-benzyl 2-methyl (S)-1,3-oxazinane-2,3-dicarboxylate→methyl (S)-1,3-oxazinane-2-carboxylate→5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl chloride→methyl (S)-3-(5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl)-1,3-oxazinane-2-carboxylate→(S)-(2-(hydroxymethyl)-1,3-oxazinan-3-yl)(5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl)methanone→5-fluoro-2-(1-(methylsulfonyl)-1H-pyrazol-3-yl)pyridine→1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazole→2-chloro-5-fluoropyridine→5-fluoro-2-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-5-yl)pyridine→5-fluoro-2-(1H-pyrazol-3-yl)pyridine→5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoic acid
本站可供应的对应中间体
同 CAS 多家在售供应横向对比；价格区间为供应方挂牌口径，实价以询价确认为准。
| 供应商 | 产品 | 价格区间 | 最小起订 | 货期 | 资质 | 操作 |
|---|---|---|---|---|---|---|
| Qualified Partner — East China API Works | 4-(4-Aminophenyl)morpholin -3-one Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Nantong cGMP Site | (S)-(+)-N-(2,3-Epoxypropyl)phthalimide Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Taizhou GMP-like Site | 5-Chlorothiophene-2-carboxylic acid Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Qualified Partner — East China API Works | 5-Chlorothiophene-2-carbonyl chloride Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Nantong cGMP Site | 2-[[(5S)-2-0x0-3-[4-(3-0xo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-1H-isoindole-1,3(2H)-dione Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Unibest Taizhou GMP-like Site | 4-[4-[(5S)-5-(Aminomethyl)-2-0xo-3-oxazolidinyl]phenyl] -3-morpholinone hydrochloride Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — | |
| Qualified Partner — East China API Works | 2-[(2R)-2-Hydroxy-3-[[4-(3-oxo-4-Morpho linyl)phenyl]aMino]propyl]-1H-isoindole-1 ,3(2H)-dione Pharmaceutical Intermediates | 询价 | 询价 | 询价 | — |
本页为中间体 CAS 注册档案：同 CAS 的多条路线登记已合并；后续供应商报价与买方需求以该 CAS 为主键撮合。